Abstract 2041P
Background
Pts with a germline BRCA pathogenic variant (gBRCA-PVs) and aHGOC report increased HAEs with platinum salts (PSs), for a possible more susceptibility of the hemopoietic stem cells to to DNA damaging agents. Also, MDS/AML cells seem to be enriched in gBRCA-PVs. The risk of PARPi-related HAEs and MDS/AML according to gBRCA-PV status in currently unknown.
Methods
We conducted a retrospective single-centre study to evaluate HAEs³G2 and MDS/AML in pts with aHGOC receving PARPi, according to the presence of a gBRCA-PV. Pts included had received a PARPi as maintenance therapy for ≥8 weeks, in any line of therapy, from Feb 2017 to Dec 2022, and had known gBRCA status. HAEs were identified by electronic medical record review, classified per CTCAE v5.0 and expressed as proportion of patients with at least one event. Onset of AML/MDS was tracked also beyond the end of treatment with PARPi (possible later occurrence), up to the last follow-up. Correlative analyses were performed (significance at p-value<0.05).
Results
166 pts were included: 95 (57%) had a gBRCA-PV. Patient characteristics, HAEs and MDS/AML are reported in in the table. At univariate analysis, gBRCA-PV status was not associated with PARPi-related HAEs, but was correlated with appearance of MDSs (9/95 vs. 1/71; p=0.04), which led to most of PARPi-discontinuations due to HAE/MDS/AML (12/95 vs. 2/71; p=0.02); 3/10 MDSs occurred during PARPi. Table: 2041P
Patient characteristics and HAEs
| gBRCA-PV+ N=95 | gBRCA-PV- N=71 | p | |
| Age at baseline, mean (SD) | 56.6 (8.9) | 60.1 (9.9) | .01 |
| Line of PARPi, median (IQR) | 2 (1-3) | 2 (1-3) | .79 |
| Type of PARPi | <.001 | ||
| Olaparib - % | 61% | 19% | |
| Niraparib - % | 21% | 29% | |
| Rucaparib - % | 9% | 1% | |
| Previous chemotherapy for other cancers - % | 10 | 4 | .79 |
| N° of cycles of PARPi, median (IQR) | 11 (8-24) | 13 (6-22) | .34 |
| HAEs - % of pts with at least one event | |||
| Any HAE* ³G2 | 47% | 28% | .67 |
| A ³G2 | 33% | 16% | .55 |
| N ³G2 | 20% | 14% | .37 |
| T ³G2 | 10% | 6% | .83 |
| MDS/AML | 10% | 2% | .16 |
| MDS | 9% | 1% | .04 |
| AML | 2% | 1% | 1.00 |
| Hospitalization for HAE | 3% | 2% | 1.00 |
| Dose reduction for HAE | 25% | 16% | .61 |
| Dose delay for HAE | 30% | 18% | .70 |
| Discontinuation for HAE or MDS/AML | 11% | 1% | .02 |
*A (anemia), N (neutropenia) or T (thrombocytopenia).
Conclusions
Unlike PSs, gBRCA-PVs are not associated with PARPi-related HAEs in pts with aHGOC. MDSs are more frequent in gBRCA-PV carriers. The interaction between gBRCA-PV, MDSs and PARPi warrants further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06